Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

lifesciences-state-drug-price-transparency-laws-webinar

Join Goodwin on December 3, 2025 for a webinar on the latest developments in State Drug Price Transparency Reporting and Prescription Drug Affordability Review Boards.

State Drug Price Transparency Laws and Prescription Drug Affordability Boards – 2025 Year-End Review Webinar

Summary

Speakers

Heath R. Ingram

Related Content

Supreme Court Declines to Review $220 Million Drug Pricing Judgment Against Eli Lilly

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

Samsung Bioepis Launches OPUVIZ in Europe

Amneal and Kashiv File IPR Petition on Omalizumab Patent

ICC Arbitration Rules Effective June 1, 2026: Key Changes and Practical Takeaways for Parties and Counsel

CHMP Adopts Positive Opinion for Ranibizumab Biosimilars VISLYFA and REXATILUX

Eli Lilly Expands Vaccine Portfolio by Acquiring Three Developers

Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Goodwin Advises Incyte in Expanded Molecular AI Collaboration and License Agreement With Genesis Valued at More Than $1 Billion

Goodwin Advises Ascidian Therapeutics on a Global Research Collaboration with Eli Lilly for Up To $1.9 Billion

Goodwin Advises Relay Therapeutics on Pricing of $316 Million Public Offering of Common Stock

Goodwin Recognized in IAM Patent 1000 2026 for Patent Law Excellence

Goodwin Advises Jefferies, TD Cowen, Stifel and Van Lanschot Kempen in Connection With €84 Million Private Placement of Valneva SE

SCAP Hologram Announces Definitive Agreement For Sale of Assets To DePuy Synthes

Goodwin Advises LimmaTech Biologics on $780 Million Acquisition by Lilly

Life Sciences